However, some commissioners were concerned that hunters taking a second buck in non-pilot counties would result in "data ...

FLUX 3 is jointly trained across those modalities rather than assembling separate image, video and audio models behind a common interface.

MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today unveiled the first public demonstration of ReefIQ™, its biological context layer for AI drug discovery, running on ...

Google is adding personalized AI avatars to Vids that let users create videos starring a digital version of themselves, ...

American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist Additional presentations related to ...

WASHINGTON, April 28 (Reuters) - The U.S. Food and Drug Administration launched a pilot program on Monday aimed at allowing the ‌agency to monitor clinical trial data in real time, a step the agency ...

Vimeo has disclosed that data belonging to some of its customers and users has been accessed without authorization following the recent breach at the Anodot data anomaly detection company. The video ...

See how Arizona lets investors own law firms In almost every U.S. state, people who aren't lawyers can't own a law firm. Through Arizona’s “Alternative Business Structures” program, you can.

The technical failure coincided with TikTok’s ownership transition, leading users to question whether videos criticizing ICE raids in Minnesota were being intentionally censored. TikTok is currently ...

Data Formulator is an AI-powered tool for analysts to iteratively explore and visualize data. Started with data in any format (screenshot, text, csv, or database), users can work with AI agents with a ...

Good day, and thank you for standing by. Welcome to the Structure Therapeutics top line results from the aleniglipron Phase II Access Program. [Operator Instructions] Please be advised that today's ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...